STOCK TITAN

Quest Diagnostics Inc - DGX STOCK NEWS

Welcome to our dedicated page for Quest Diagnostics news (Ticker: DGX), a resource for investors and traders seeking the latest updates and insights on Quest Diagnostics stock.

Quest Diagnostics Incorporated (DGX) provides essential diagnostic insights and testing services across the U.S. healthcare system. This news hub aggregates official press releases, financial updates, and strategic developments from one of America's leading clinical laboratory networks.

Investors and healthcare professionals will find timely updates on earnings reports, partnership announcements, and technological advancements in diagnostic testing. Our curated news feed includes regulatory milestones, service expansions, and innovations leveraging DGX's vast clinical database.

Key updates cover emerging trends in precision diagnostics, laboratory network growth, and healthcare collaborations. Users can track the company's progress in cancer detection, genomic testing, and data-driven health solutions through verified primary sources.

Bookmark this page for direct access to DGX's latest financial performance data, leadership changes, and operational developments. Visit regularly to stay informed about how Quest Diagnostics continues shaping diagnostic medicine through clinical excellence and strategic initiatives.

News
Rhea-AI Summary
Quest Diagnostics (DGX) employee shares their journey to the company, highlighting the impact of a chance encounter on their career.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.64%
Tags
none
-
Rhea-AI Summary
Quest Diagnostics (NYSE:DGX) launches a groundbreaking consumer-initiated blood test for PFAS chemicals, offering consultation with a physician. The test targets individuals at risk of elevated PFAS exposure, as identified by National Academies of Sciences, Engineering, and Medicine. Organizations can also utilize the test for workforce, community, and research population screening.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.51%
Tags
none
-
Rhea-AI Summary
Quest Diagnostics collaborates with Western University to offer no-cost diagnostic testing for rare autoimmune diseases, leading to potentially life-saving diagnoses. The Biopsies Save Lives program under the Quest for Health Equity initiative has helped 3 patients so far, breaking down financial barriers and providing critical support to underserved communities in Southern California.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.61%
Tags
none
Rhea-AI Summary
Quest Diagnostics (NYSE:DGX) has been recognized as one of FORTUNE's World's Most Admired Companies in 2024 for the tenth consecutive year. The company scored high in people management, use of corporate assets, and social responsibility, standing out in the 'Health Care: Pharmacy and Other Services' industry.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.18%
Tags
none
-
News
Rhea-AI Summary
Quest Diagnostics CEO Jim Davis receives a heartfelt letter from a patient after 30 years of service, highlighting the impact of dedicated Patient Services colleagues.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.39%
Tags
none
-
Rhea-AI Summary
Quest Diagnostics Incorporated (DGX) announced that Sam Samad, CFO, will speak at the Barclays Global Healthcare Conference to discuss the company's strategy and performance.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.39%
Tags
conferences
Rhea-AI Summary
Pack Health, a Quest Diagnostics company, collaborates with Instacart to provide grocery delivery services to individuals in coaching programs, addressing social determinants of health. The partnership aims to improve food access and healthy eating habits for underserved communities, offering nutrition education, coaching, and fresh food delivery. This initiative combines Instacart's reach and technology with Pack Health's expertise in patient engagement, providing a comprehensive nutrition solution for health plan members.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.37%
Tags
none
-
Rhea-AI Summary
Freenome secures $254 million in funding led by Roche to advance cancer detection tests. The funds will support the development of early cancer detection tests and expand the multiomics platform capabilities. Investors include Roche, a16z Life Sciences Growth Fund, and Quest Diagnostics (DGX). Freenome aims to revolutionize personalized healthcare with groundbreaking blood-based screening technology.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.56%
Tags
none
-
Rhea-AI Summary
Quest Diagnostics (DGX) launches MelaNodal Predict™, a gene expression test to aid melanoma treatment decisions. The test shows over 90% survival rate for low-risk patients. The partnership with SkylineDx aims to provide personalized care and reduce unnecessary surgeries.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.65%
Tags
none
Rhea-AI Summary
Quest Diagnostics (DGX) introduces a consumer-initiated, physician-ordered blood-draw test for PFAS chemicals, addressing elevated exposure risks. The test detects and measures PFAS identified by National Academies of Sciences, Engineering, and Medicine, catering to various organizations for workforce, community, and research population testing.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.58%
Tags
none
Quest Diagnostics Inc

NYSE:DGX

DGX Rankings

DGX Stock Data

18.18B
111.14M
0.44%
93.75%
2.31%
Diagnostics & Research
Services-medical Laboratories
Link
United States
SECAUCUS